Evidence map›Paper›PMID 36683420›Full record

ArticleJournal of intensive care medicine2023

Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study.

Ohoud Aljuhani, Ghazwa B Korayem, Ali F Altebainawi, Abdullah Al Harthi, Hisham A Badreldin, Muath A Alsalloum, Khalid Eljaaly, Aisha Alharbi, Rowina Aljehani, Ramesh Vishwakarma and 13 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Journal of intensive care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 3 countries.

Ohoud AljuhaniDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Ghazwa B KorayemDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Ali F AltebainawiPharmaceutical Care Services, King Salman Specialist Hospital, Hail Health Cluster, Ministry of Health, Hail, Saudi Arabia.
Abdullah Al HarthiPharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Hisham A BadreldinPharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Muath A AlsalloumDepartment of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Khalid EljaalyDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Aisha AlharbiPharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
Rowina AljehaniPharmaceutical Services Department, Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.
Ramesh VishwakarmaNorwich Medical School, University of East Anglia, Norwich, UK.
Abeer A AlenaziPharmaceutical Care Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Mai AlalawiDepartment of Pharmaceutical Sciences, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia.
Abdulrahman AlissaPharmaceutical Care Services, King Abdullah bin Abdulaziz University Hospital, Riyadh, Saudi Arabia.
Kholoud Al AamerPharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Huda Al EnaziPharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Mohammed AlmusallamCollege of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Abdulaziz AlshehriCollege of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Rawan BukhariPharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
Ghaday AlasmariPharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
Maha M AlQahtaniCollege of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Sultanah Al ShammariPharmaceutical Care Department, Ministry of Health, Ar'ar, Saudi Arabia.
Hatim O AlsulaymiPharmaceutical Care Services, King Salman Specialist Hospital, Hail Health Cluster, Ministry of Health, Hail, Saudi Arabia.
Khalid Al SulaimanPharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.ORCID 0000-0002-5547-2043
King Abdulaziz Medical City · SAKing Saud bin Abdulaziz University for Health Sciences · SASoliman Fakeeh Hospital · SAUniversity of Ha'il · SAKing Abdulaziz Hospital · SAKing Abdulaziz University · SAMedical University of South Carolina · USMinistry of Health · SAPrincess Nourah bint Abdulrahman University · SARiyadh Armed Forces Hospital · SAUniversity of Arizona · USUniversity of East Anglia · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19AdultAntibodies, Monoclonal, HumanizedCohort StudiesCOVID-19 Drug TreatmentCritical IllnessHumansIntensive Care UnitsPropensity ScoreRetrospective StudiesSARS-CoV-2Antibodies, Monoclonal, Humanizedtocilizumabacute kidney injuryCOVID-19critically illIL-6 inhibitorsintensive care units (ICUs)liver injurymortalitymultiorgan dysfunctionSARS-CoV-2tocilizumab

Identifiers

PMID36683420
PMCPMC9892816
OpenAlexW4317781084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.